Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) has a beta value of 1.49 and has seen 1.09 million shares traded in the last trading session. The company, currently valued at $2.14B, closed the last trade at $16.23 per share which meant it lost -$0.53 on the day or -3.16% during that session. The CNTA stock price is -17.62% off its 52-week high price of $19.09 and 52.25% above the 52-week low of $7.75.
The consensus among analysts is that Centessa Pharmaceuticals plc ADR (CNTA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 6 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.35.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Sporting -3.16% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CNTA stock price touched $16.23 or saw a rise of 6.13%. Year-to-date, Centessa Pharmaceuticals plc ADR shares have moved -3.10%, while the 5-day performance has seen it change 4.37%. Over the past 30 days, the shares of Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) have changed -5.86%.
Wall Street analysts have a consensus price target for the stock at $23, which means that the shares’ value could jump 29.43% from current levels. The projected low price target is $19.0 while the price target rests at a high of $28.0. In that case, then, we find that the current price level is -72.52% off the targeted high while a plunge would see the stock gain -17.07% from current levels.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
The company’s shares have gained 10.94% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -100.00%.
Earnings growth for 2025 is a modest 2.83% while over the next 5 years, the company’s earnings are expected to decrease by -3.40%.
CNTA Dividends
Centessa Pharmaceuticals plc ADR is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders
The top two institutional holders are MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with over 19.96 million shares worth more than $180.27 million. As of 2024-06-30, MEDICXI VENTURES MANAGEMENT (JERSEY) LTD held 18.233% of shares outstanding.
The other major institutional holder is GENERAL ATLANTIC, L.P., with the holding of over 9.68 million shares as of 2024-06-30. The firm’s total holdings are worth over $87.43 million and represent 8.8427% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Price (T.Rowe) Health Sciences Fund and Fidelity Select Portfolios – Biotechnology . As of Dec 31, 2024 , the former fund manager holds about 2.64% shares in the company for having 3.48 shares of worth $56.43 million while later fund manager owns 2.98 shares of worth $48.31 million as of Dec 31, 2024 , which makes it owner of about 2.26% of company’s outstanding stock.
